Key Drivers
- Higher lows
- $14 support
- Breakout needed
AIAI Summary
RMT should now be viewed less as a pure income fund and more as a conditional small-/micro-cap recovery bet: if it can keep NAV compounding, hold above $14.00, and narrow the persistent discount on improving volume, upside could re-rate quickly, but weak liquidity or fading small-cap leadership would leave the discount and volatility intact.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •$14 support
- •Breakout needed
Over the last month, RMT rose 3.6% with higher lows and $14.00 support intact, but it still needs a clean breakout above $14.68 to confirm a stronger uptrend.
Pulled back after testing $14.68 on 2026-07-01, showing a brief momentum fade
Sentiment & News
Key News Insights:
- •Strong returns
- •NAV discount
- •Pipeline expansion
Royce Micro-Cap Trust posted strong recent returns but still traded below NAV, while Resolution Therapeutics expanded its macrophage therapy pipeline with new delivery tests and data expected later this year.
The fund's performance and discount may support investor interest, while Resolution Therapeutics' early-stage pipeline progress adds long-term upside but remains highly developmental
Similar Companies in Financial Services
Other companies in the same sector with AI ratings